Interpretation of the 2023 updates to the National Institute for Health and Care Excellence Guidelines on Cardiovascular Disease:Risk Assessment and Reduction,Including Lipid Modification
Interpretation of the 2023 updates to the National Institute for Health and Care Excellence Guidelines on Cardiovascular Disease:Risk Assessment and Reduction,Including Lipid Modification
This article provides an interpretation of the newly added sections in the 2023 guidelines titled Cardiovascular Disease:Risk Assessment and Reduction,Including Lipid Modification published by the National Institute for Health and Care Excellence(NICE).The new sections cover various aspects such as risk assessment tools for the primary prevention of cardiovascular disease(CVD),cardiovascular protective diets,and the use of aspirin and statins for both primary and secondary prevention of CVD.This interpretation aims to provide scientific guidance for CVD risk assessment and reduction in China.
维普
万方数据